SCHEMBL22018267

SCHEMBL22018267

COC(=O)C1(C(=O)OC)Cc2ccc(Br)cc2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
POLB P06746 2/20 0.40
MAPT P10636 2/20 0.40
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TDP2 O95551 1/20 0.36
HSD17B3 P37058 2/20 0.35
SRD5A1 P18405 1/20 0.35
SRD5A2 P31213 1/20 0.35
PTPN2 P17706 1/20 0.35
PTPN1 P18031 1/20 0.35
PTPN6 P29350 1/20 0.35
NR4A2 P43354 1/20 0.35
ABHD6 Q9BV23 1/20 0.35
CMA1 P23946 1/20 0.34
AHR P35869 1/20 0.34
BRD4 O60885 1/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28683494 0.85 KDM4E (0.40) KDM4EPOLBMAPTKMT2AMEN1
SCHEMBL25959828 0.85 KDM4E (0.43) KDM4EPOLBMAPTKMT2AMEN1
SCHEMBL30758533 0.84 MAPT (0.39) KDM4EPOLBMAPTKMT2AMEN1
Hydrochloric Acid SCHEMBL3497852 0.83 MAPT (0.38) KDM4EPOLBMAPTKMT2AMEN1
SCHEMBL31537527 0.83 ESR1 (0.40) MAPTKMT2AMEN1ALDH1A1TDP2
SCHEMBL795467 0.83 ESR1 (0.40) MAPTKMT2AMEN1ALDH1A1TDP2
SCHEMBL10875993 0.80 MEN1 (0.40) KMT2AMEN1ALDH1A1
SCHEMBL19586030 0.79 SRD5A1 (0.42) KDM4ETDP2HSD17B3SRD5A1SRD5A2
SCHEMBL12203632 0.78 MEN1 (0.44) KDM4EPOLBMAPTKMT2AMEN1
SCHEMBL19586031 0.77 HPGD (0.40) KDM4EPOLBMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057957-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2025-02-20 US disclosed
EP-4483875-A2 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2025-01-01 EP disclosed
EP-3454862-B1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS INC (US) 2024-09-11 EP disclosed
US-12048748-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2024-07-30 US disclosed
US-20230095223-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-03-30 US disclosed
US-11185592-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2021-04-15 US disclosed
US-10660968-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2020-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11185592-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A KDM4E 1930/4885POLB 3779/4885MAPT 2629/4885
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A KDM4E 1930/4885POLB 3779/4885MAPT 2629/4885
US-20250057957-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A KDM4E 1930/4885POLB 3779/4885MAPT 2629/4885
US-10660968-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A KDM4E 1930/4885POLB 3779/4885MAPT 2629/4885
US-20230095223-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A KDM4E 1930/4885POLB 3779/4885MAPT 2629/4885
US-12048748-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A KDM4E 1930/4885POLB 3779/4885MAPT 2629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.